Generic drug
Fondaparinux price, strengths & recalls
Pharmacies pay $339.81 for 8 mL of Fondaparinux 12.5 mg/mL, 0.8 mL prefilled syringe this week, and from $110.81 to $339.81 across its 3 priced strengths and forms. 5 manufacturers make it. It has 1 recall on record, none ongoing. Its official label last changed on September 13, 2021.
Generic- Fair cash price
- $401.28
- Strengths
- 3
- Makers
- 5
- Updated
- Nov 11
Fondaparinux price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay | ||
|---|---|---|---|---|
| 5 mg/mL, 0.5 mL prefilled syringe | $22.16 | $110.81 / 5 mL | ||
| 12.5 mg/mL, 0.4 mL prefilled syringe | Not priced this week | |||
| 12.5 mg/mL, 0.6 mL prefilled syringe | $42.35 | $254.09 / 6 mL | ||
| 12.5 mg/mL, 0.8 mL prefilled syringe | $42.48 | $339.81 / 8 mL | ||
Supply status: shortages & recalls
Recalls
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Fondaparinux
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use FONDAPARINUX SODIUM INJECTION safely and effectively. See full prescribing information for FONDAPARINUX SODIUM INJECTION. FONDAPARINUX SODIUM injection for subcutaneous use Initial U.S. Approval: 2001
WARNING: SPINAL/EPIDURAL HEMATOMAS
Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH), heparinoids, or fondaparinux sodium and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:
use of indwelling epidural catheters
concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, or other anticoagulants
a history of traumatic or repeated epidural or spinal puncture
a history of spinal deformity or spinal surgery
Optimal timing between the administration of fondaparinux sodium and neuraxial procedures is not known.
Monitor patients frequently for signs and symptoms of neurologic impairment. If neurologic compromise is noted, urgent treatment is necessary.
Consider the benefit and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis. [see Warnings and Precautions (5.1) and Drug Interactions (7)]
WARNING: SPINAL/EPIDURAL HEMATOMAS
See full prescribing information for complete boxed warning.
Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH), heparinoids, or fondaparinux sodium and are receiving neuraxial anesthesia or undergoing spinal puncture.
These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:
· use of indwelling epidural catheters
· concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, or other anticoagulants
· a history of traumatic or repeated epidural or spinal puncture
· a history of spinal deformity or spinal surgery
Monitor patients frequently for signs and symptoms of neurologic impairment. If neurologic compromise is noted, urgent treatment is necessary.
Consider the benefit and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis. [see Warnings and Precautions (5.1) and Drug Interactions (7)]
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA021345 · Mylan Ireland Ltd
- First approved
- December 7, 2001 (25 years ago)
- Latest approved change
- December 23, 2024
- Approved label
- PDF, Dec 27, 2024
- Generic makers
- 4 approved generic applications on the market
Fondaparinux questions
How much does fondaparinux cost without insurance?
Pharmacies pay about $339.81 for 8 mL of fondaparinux 12.5 mg/mL, 0.8 mL prefilled syringe ($42.48 per mL). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $401.28. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is fondaparinux in shortage?
No shortage is reported for fondaparinux right now. We check the national shortage list every day.
Has fondaparinux been recalled?
1 recall on record, none ongoing. Recalls name specific lots - check yours.
When did the fondaparinux label last change?
The official label was last updated on September 13, 2021 (version 16). See what changed.
Talk about fondaparinux
No comments yet. Questions, tips, what worked for you - start the conversation.